← Metformin × blood pressure

TrialCardiovascular diabetology2021

Comparison of the clinical effect of empagliflozin on glycemic and non-glycemic parameters in Japanese patients with type 2 diabetes and cardiovascular disease treated with or without baseline metformin.

Atsushi Tanaka et al.PubMed ↗Full text ↗Publisher ↗

  • Baseline metformin use (within empagliflozin arm)looks good hereLower body mass index, no clear link with systolic blood pressure.Correlation only, not a test of it.

What moved togetherboth groups pooled, not the treatment’s effect

Correlation, not cause

Baseline metformin use (within empagliflozin arm) went with lower body mass index

−0.54−1.07 to −0.01

baseline metformin use (within empagliflozin arm) vs nonusers of baseline metformin (within empagliflozin arm), in patients treated with empagliflozin

As reported

difference −0.54, 95% CI −1.07 to −0.01 · the paper's word: Reduction in body mass index (BMI)

Correlation · may be no link

No clear link with systolic blood pressure

−8.50−17.7 to +0.60

baseline metformin use (within empagliflozin arm) vs metformin-naïve patients (within empagliflozin arm), in patients treated with empagliflozin

As reported

difference −8.50, 95% CI −17.7 to 0.60 · the paper's word: decrease in systolic blood pressure from baseline levels

Who was studied, and how

105people with cardiovascular disease, in this paper

Already taking baseline metformin use (within empagliflozin arm), or nottheir own situation, not assigned

on baseline metformin use (within empagliflozin arm)
nonusers of baseline metformin (within empagliflozin arm)

Baseline metformin use (within empagliflozin arm) went with lower body mass index−0.54

No clear link with systolic blood pressure−8.50

correlation, not a test

the abstract, start to end

… metformin, relative to nonusers (- 0.54 [95% CI - 1.07 to - 0.01] kg/m …

… patients (group difference - 8.5 [95% confidence interval (CI) - …

← favours treatmentfavours comparator →
could be chance
Reduction in body mass index (BMI)baseline metformin use (within empagliflozin arm) vs nonusers of baseline metformin (within empagliflozin arm), in patients treated with empagliflozin
−0.54−1.07 to −0.01
Decrease in systolic blood pressure from baseline levelsbaseline metformin use (within empagliflozin arm) vs metformin-naïve patients (within empagliflozin arm), in patients treated with empagliflozin
−8.50−17.7 to 0.60
MetforminSGLT2 inhibitorsBody weight & compositionBlood pressure
1 / 4

6 papers cite it

2021
2022
2023
2024
2025
2026
this papertrialcites it
Full record →Abstract, authors, funding and every citing paper · PMID 34332584